BPC-157 is under FDA advisory review in July 2026, and FDA staff documents recommend caution because human safety and effectiveness data are limited
pmid:12026195 9
This is why weekly dosing maintains therapeutic levels in your bloodstream
We have recently demonstrated that ALCAR has angiopreventive activities on endothelial cells acting on the VEGF/VEGFR2 and CXCR4/CXCL12 axes [30]
Young: Particularly after, like, a drug treatment, is gonna be fat instead of muscle mass because, obviously, right, like, maybe with physical exercise, youre still maintaining those good behaviors a little bit more with exercising more regularly, or same with eating patternsmaybe youre still kind of, like, eating a little bit better than you were before, even if you fully stop a diet or, like, an intensive training regimen for exercise
Robert Popovian 05:38 What I will tell patients is that the Food and Drug Administration has approved biosimilars and has found biosimilars to be of equal safety, efficacy, and purity